Circular 12 of 2024_IMPLEMENTATION PLAN FOR RE-REGISTRATION OF HUMAN ALLOPATHIC MEDICINES RE-REGISTRATION FEES

Circular 11 of 2024-SYSTEM CONFIGURATION TO ZIG

Circular 10 of 2024-Prevention of Diethylene Glycol (DEG) and Ethylene Glycol (EG) Contamination in Pharmaceticals

Circular 9 of 2024 – Wholesale Dealers Permit Renewals

Circular 8 of 2024-Upgrade on the MCAZ Imports/Exports Module

Circular 7 of 2024 – Renewal of Premises Licences for Pharmacies

Circular 6 of 2024 – Notification of the Implemetation Plan for Grouped of Variations and Variation Notification

Circular 5 of 2024 – Publication of Cancelled Wholesale Dealer’s Permits, Pharmacy Licences and Persons’ Licences

Circular 4 of 2024 – Implementation Plan for Re-Registration of Human Allopathic Medicines – Extension of Re-Registration Fee Waiver

Circular 3 of 2024 – Re-Opening of the Cash Receipting Office

Circular 2 of 2024 – Renewal of Licences for the Production of Cannabis for Medicinal and Scientific Use

Circular 1 of 2024 – Submission of Annual Returns

Circular 24 of 2023 :Bulk importation of unregistered medicines

Circular 23 of 2023 – Acquiring Raman Spectroscopy Signatures from Pharmaceutical Wholesalers and Distributors

Circular 27 of 2023 – 2023 Annual Shutdown Notice

Circular 26 of 2023 – Processing of applications for registrations of medicines

Circular 21 of 2023 – Implementation Plan for Re-Registration of Human Allopathic Medicines- Extension of Fees Waiver

Circular 22 of 2023: Publication of Canceled Wholesale Dealer’s Permits, Pharmacy Licences and Person’s Licences

Circular 17 of 2022: CBD Products

Circular 18 of 2023: Fees for Laboratory Analysis Of Complementary Medicines

Circular 20 of 2023: Fees schedule

Circular 19 of 2023: Implementation Plan for Re-Registration of Human Allopathic Medicines _Proposed Fees

Circular 12 of 2023 : Regulatory Alert Regarding the Selling of Specially Restricted Preparations and Thalidomide

Circular 13 of 2023 Suspension of the Small Business Support Function Till Further Notice

Circular 25 of 2022- Notification of issuance of revised registration certificates for variations at re-registration

Circular 11 Of 2023 – Follow-Up Plan for Registration of Human Allopathic Medicines

Circular 14 of 2022 – Implementation Plan for Re-Registration of Human Allopathic Medicines

Circular 6 of 2023 – Instruction to quarantine all Pholcodine-containing products

CIRCULAR 5 OF 2023 -INSTRUCTION TO QUARANTINE TETRACYCLINE HYDROCHLORIDE OPHTHALMIC OINTMENT USP 1% MANUFACTURED BY GALENTIC PHARMA (INDIA) PVT, LTD, R-673, T.T.C. MIDC RABALE, THANE-BELAPUR ROAD, NAVI MUMBAI-400701, MAHARASHTRA, INDIA

Circular 4 of 2023 – Change of Value Added Tax (TAX) Rate from 14.5% to 15%

Circular 01 of 2023- Renewal of Permits and Persons licences for Wholesale dealers, Sales Representative and Pharmacy Technicians

Circular 24 of 2022- Importation of Medicines

Circular 23 of 2022- Importation of Medicines

Circular 20 of 2022 CBD products clarification

Circular 21 of 2022 – Invitation to stakeholders meetings

Circular 19 of 2022 – Fees Schedule

Circular-15-of-2022-Safety-measures-for-sodium-valproate-and-the-risk-of-congenital-malformations-in-neonates-and-neurodevelopmental-disorders-in-children-exposed-to-sodium-valproate-during-pregnancy

Circular 13 of 2022 Pharmacovigilance system requirements for Pharmaceutical Industry

Circular 11 of 2022 Revised MCAZ Clinical Trial Guidelines

Circular 9 of 2022 Inspection of Premises prior to renewal of Licences and Permits

Circular 8 of 2022 -Publication of Cancelled Wholesale Dealers’ Permit and Persons’ Licences

circular 06 of 2022- Renewal of Wholesale Dealers

Circular 02 of 2022- Renewal of Pharmacies

Circular 3 of 2022 – Clarification of Conditions for Medicines Registration Requirements and Subsequent Expansion of Registration Certificate, Section 15 Format Annexure

Annex1-Template-for-comments-on-Draft-Guideline-for-market-Authorization-Renewal

Circular 5 of 2022 – Publication of Cancelled Premises and Persons’ Licences.

Circular 16 of 2021 – Use of Ivermectin human oral formulations for prevention and or treatment of COVID 19

Circular 1 of 2022 – Publication of product Information for Registered medicinal Products (Summary of Product Characteristics

Circular 4 of 2020 – Preventive Measures to Reduce the Spread of COVID-19 (Coronavirus) by the Medicines Control Authority of Zimbabwe (MCAZ)

Circular 3 of 2020-Renewal of Premises Licences- Pharmacies